The U.S. Food and Drug Administration gave the green light Friday to the first generic version of the blockbuster diabetes drug Actos (pioglitazone hydrochloride). It’s often taken as a second-line treatment for type 2 diabetes for those who don’t get a big enough blood sugar level drop with a first-line therapy such as metformin.